Superb! Studies show when administered as boosters, mono- and bivalent Omicron BA.4/BA.5-adapted vaccines ENHANCE neutralization breadth, and in a bivalent format, may also have the potential to confer protection to individuals with NO pre-existing immunity against SARS-CoV-2!🧵
Conversation
Source:
•Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice: biorxiv.org/content/10.110
1
19
155
Researchers recently reported that breakthrough infections of vaccinated individuals with Omicron sublineages BA.1 and BA.2 were associated with distinct patterns of cross-neutralizing activity against SARS-CoV-2 variants of concern (VOCs). BA.2 breakthrough infection mediated
1
6
102
overall stronger cross-neutralization of BA.2 and its descendants (BA.2.12.1, BA.4, and BA.5) compared to BA.1 breakthrough infection.
Here, researchers characterized the effect of Omicron BA.4/BA.5 S (spike) glycoprotein exposure on the magnitude and breadth of the
1
8
100
neutralizing antibody response upon breakthrough infection in vaccinated individuals and in mice upon booster vaccination.
They showed that immune sera from triple mRNA-vaccinated individuals with subsequent Omicron BA.4/BA.5 breakthrough infection displayed broad AND robust
1
6
96
neutralizing activity against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5. Administration of a prototypic BA.4/BA.5-adapted mRNA booster vaccine to mice following SARS-CoV-2 wild-type strain-based primary immunization was ALSO associated with similarly broad
2
12
98
neutralizing activity. Immunization of naïve mice with a bivalent mRNA vaccine (wild-type + Omicron BA.4/BA.5) induced strong and broad neutralizing activity against Omicron VOCs and previous variants.
1
5
90
These findings suggest that when administered as boosters, mono- and bivalent Omicron BA.4/BA.5-adapted vaccines may enhance neutralization breadth, and in a bivalent format may also have the potential to confer protection to individuals with no pre-existing immunity against
3
16
133
SARS-CoV-2. Chise, what does this all mean? Let’s break it down! READ ⬇️
7
18
145
While we are here, I recommend reading ’s breakdown of this study. He discusses the impact of other variants on the rise (like BA.2.75.2 or BQ.1.1 which ARE still sub-variants of Omicron) and these vaccines (“DON’T write the vaccines off.”)
•
Quote Tweet
IMAGINE THAT
Anyway: please get your boosters.
Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice biorxiv.org/content/10.110
Show this thread
1
18
122
So, what can we reasonably grasp from this study? A couple of things. For one, bivalent boosters will SIGNIFICANTLY enhance broad protection against Omicron AND its sub-variants AND this includes transmission. From the study researchers:
Together these findings add to our current understanding on how vaccine boosters adapted to Omicron VOCs in a bivalent format shape immunity and suggest that exposure to Omicron BA.4/.5 S glycoprotein may confer heightened protection against the currently circulating and
1
6
93
potential future Omicron VOCs.
Conclusion: “Our finding that immunization of naïve mice with the BNT162b2/BA.4/.5 bivalent vaccine elicits strong neutralizing antibody responses against the wild-type strain as well as Omicron and non-Omicron VOCs suggest that this bivalent
2
7
135
approach may confer broad protection to unvaccinated individuals who have not been previously infected with SARS-CoV-2.”
•Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice: biorxiv.org/content/10.110
11
12
139
Is this the Pfizer bivalent that is currently available in the US targeted at B4/5?. How does it compare to the Moderna bivalent mRNA-1273.214 for B1?
1
1
That’s correct! Also I have
Quote Tweet
Okay, so maybe that’s not all. Why? BECAUSE this lovely study just came out yesterday.
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.
•biorxiv.org/content/10.110
Show this thread




